informed consent was obtained from all patients, the study was in accordance with the Declaration of Helsinki, and I followed the Consolidated Standard of Reporting Trials (CONSORT) recommendations for reporting randomised clinical trials.
Consecutive American Society of Anesthesiologists physical status 1 to 3 patients, aged 16 to 80 years, scheduled for elective shoulder surgery under the care of the principal investigator from January through December 2012 at the Southern Cross Brightside Hospital were recruited. A research assistant made the initial invitation for participation, but definitive recruitment was by the prinicipal investigator. Exclusion criteria included interscalene block refusal, severe respiratory disease, known amide local anaesthetic drug allergy, non-steroidal anti-inflammatory drug intolerance and preoperative opioid therapy administered for >1 month prior to surgery. The design was a single centre, prospective, randomised, observer-blinded trial.
Randomisation
One hundred and fifty-six patients were randomly assigned to three groups. Randomisation to the three groups was performed by a research assistant away from the study procedures and implemented with a computer-generated random number in blocks of 20. Randomisation was not stratified by procedure. Group concealment was by 156 pre-prepared sealed opaque envelopes, opened just before catheter placement.
Study interventions
Random assignment was to an end-hole, triplehole or six-hole catheter (groups 1, 3, 6). All were 20G polyamide catheters manufactured by B Braun Ltd (Bethlehem, PA, USA). The triple-orifice catheter was the standard triple-orifice catheter supplied with the Contiplex Tuohy ® kit. The end-hole catheter was the standard end-hole catheter incorporated into the Contiplex D ® kit-the rest of that kit was discarded. The six-hole catheter was a new, individually supplied, six-hole polyamide catheter featuring a soft polyurethane outer coating and a 4 cm tapered tip (Perifix ONE ® catheter). The polyurethane coating is said to increase catheter tip flexibility. The triple-hole and six-hole catheter orifices are located approximately 0.5, 1 and 1.5 cm from the catheter tip and radially orientated at 12, 4 and 8 o'clock; the six-hole orifices are a similar size and arranged with the same configuration as the triple-hole design in pairs at the three locations. All catheters were also cut at the proximal end to a length of 25 cm to minimise the flow pressure gradient between each catheter's proximal end and orifice(s).
Catheter placement
The principal investigator, who was experienced with this procedure, performed all catheter placements as previously described in several publications 1,5-7 and at www.ultrasoundblock.com (accessed March 17, 2013) . Catheter placement first involved a modified superficial cervical plexus block; an out-ofplane 'anterolateral' approach; and specifically: 1. a 4 cm 18G insulated Tuohy needle (Contiplex Tuohy ® ) 'tunnelled' subcutaneously such that 4 cm of needle was under the skin, 2. concomitant neurostimulation (0.8 mA, 2 Hz) necessitating a brief deltoid, biceps or triceps motor response to confirm the target nerve roots/ trunks. Sustained motor responses at <0.5 mA were only sought when sonographic imaging of the roots was suboptimal, 3. injection of 10 ml dextrose 5% via the needle immediately before catheter advancement, 4. blind catheter advancement 5 to 7 cm beyond the needle tip and then, after needle removal, catheter withdrawal until 3 cm remained past the original needle tip position (catheter fixed 4+3=7 cm at the skin), and 5. all interscalene local anaesthetic administered via the catheter.
Anaesthesia and analgesia
A standardised technique was used. Intravenous sedation, up to midazolam 2 mg and alfentanil 0.5 mg, was administered before catheter placement. Intraoperative multimodal analgesia consisted of intravenous parecoxib 40 mg and dexamethasone 8 mg.
Intraoperative management
General anaesthesia was also standardised using a laryngeal mask airway and spontaneous desflurane respirations (end-tidal minimum alveolar concentration 0.8 to 1.0). Following general anaesthesia induction and approximately ten minutes after catheter placement, but before surgery, ropivacaine 0.375% 15 ml was administered via the catheter over approximately two to three minutes (flow rate expected >400 ml/hour) 8 . This combination of local anaesthetic volume and concentration was chosen as a compromise between a dose low enough to realistically detect a difference between groups for the primary outcome (pain on emergence) and a dose high enough to avoid unacceptable recovery room pain 5, 6 . No long-acting opioid was administered intraoperatively; however, alfentanil 0.25 mg was given if the respiratory rate was >25. 
PACU protocol
In the post-anaesthesia care unit (PACU), patients reporting a numerical rating pain score (NRPS, 0 to 10) of more than two were given a bolus of lignocaine 1.5% 15 ml via the catheter and intravenous fentanyl 25 µg pro re nata every one to two minutes. If pain persisted 30 minutes after this bolus, the catheter was replaced with the same catheter type and a further 15 ml of ropivacaine 0.375% was given via this catheter.
Postoperative management
An elastomeric pump was used for the first six months of the study (PainBuster ® pump, Surgical Synergies, Auckland, New Zealand), but because of supply issues with that device, an electronic pump was used for the last six months (ambIT ® pump, Summit Medical Products, South Sandy, UT, USA). Both were set to deliver ropivacaine 0.2% at 2 ml/hour with patient-controlled 5 ml boluses (bolus flow rate=100 to 150 ml/hour) of up to one bolus every hour. From the onset of shoulder pain until 48 hours postoperatively, patients were instructed to activate the ropivacaine bolus button "on the clock" every six hours irrespective of the NRPS 7 . Additional 5 ml boluses were administered in-between mandatory six-hourly boluses if the NRPS increased to more than two. Multimodal analgesia was continued after surgery: paracetamol (1 g every six hours) and slow-release diclofenac (75 mg every 12 hours) if any postoperative pain occurred; slow-release tramadol (100 mg every 12 hours) if the NRPS increased to >2 despite regular paracetamol, diclofenac and two consecutive ropivacaine boluses within three to four hours. Discharge home occurred either on the day of surgery or the morning of postoperative day one (all open procedures).
Study endpoints
The primary endpoint was the proportion of patients reporting pain in the PACU. The main secondary endpoints were time to first pain, numerically rated pain and tramadol consumption during the first 24 hours.
Data collection and blinding
The principal (operating) investigator recorded the needle endpoint used for catheter placement (ultrasound or neurostimulation). He also recorded whether there was "excessive" resistance to catheter advancement: defined as marked resistance to catheter advancement beyond the needle tip despite a 1 to 2 mm needle retraction. The principal investigator also recorded the number of alfentanil 0.25 mg boluses administered during surgery. The patient's primary PACU nurse recorded the emergence NRPS in the shoulder, arm or elbow and details of PACU interventions (local anaesthetic bolus, fentanyl rescue). A research assistant phoned all subjects at 24 postoperative hours and questioned for ropivacaine bolus demands, supplemental tramadol consumption, time to first pain, NRPS (worst and "average" pain during the previous 24 hours), numerically rated numbness/weakness and satisfaction (0 to 10, 0=no pain, numbness/weakness, very unsatisfied; 10=worst imaginable pain, numbness/ weakness, very satisfied) during the previous 24 hours (specifically excluding pain that was present in the recovery room). Data recorded in the operating room by the principal investigator was not blinded. All subsequent data collection was patient-and observer-blinded.
Statistical analysis
An independent statistician performed all calculations. Categorical outcomes were compared using Fisher's exact test (catheter threading difficulty, intraoperative alfentanil boluses, pain in the PACU and breathlessness). Time to first pain was compared using the log-rank test for survival data. Ordinal outcomes (NRPS outcomes, tramadol consumption and ropivacaine bolus use) were compared using the kruskal-Wallis test. P values <0.05 were considered statistically significant. Two-sided tests were used for all experimental outcomes.
Other data were summarised using appropriate descriptive statistics (mean and standard deviation or mean and range for normally distributed or symmetric variables, median and interquartile ranges for skewed variables, number and proportion for categorical variables). All statistical analyses were performed using R 2.12.1 (R Project, Institute for Statistics and Mathematics, vienna, Austria).
Sample size estimates were based on a hypothesis of no difference between groups and, therefore, demonstration of equivalence of the primary outcome: the proportion of patients reporting emergence pain. I considered an arbitrary 15% difference as clinically significant. A previous study using the anterolateral approach and a similar surgical mix but using ropivacaine 0.375% 20 ml reported a 90% pain-free recovery room rate 5 . Assuming 80% power, detection of a 15% shift (9% increase; 19% decrease) in the proportion of patients pain-free in the PACU, with 95% confidence, would require 50 patients in each group (chi-square test, Statmate 2.0; GraphPad Software, San Diego, CA, USA).
We also performed three post hoc equivalence tests for the primary outcome by calculating the 90% confidence interval for the difference between the proportion of patients reporting emergence pain for each group compared with the other two groups. These limits provide estimates for which equivalence can be concluded at the 5% significance level.
RESULTS
One hundred and fifty-six patients presenting for elective shoulder surgery were enrolled: 52, 53 and 51 patients were randomised to the groups 1, 3 and 6 respectively. Patient and surgical characteristics were comparable between groups (Table 1) . Eight patients were not contactable on day one and were thus excluded (4, 2 and 2 patients in groups 1, 3 and 6 respectively). Thus, 148 patients completed the study per protocol. Two patients in the end-hole group necessitated a sustained motor response at <0.5 mA because of suboptimal brachial plexus ultrasound imaging.
Difficulty with catheter threading was more common in the end-hole group (end-hole=19% versus triple-hole=6%, six-hole=0%, P <0.001; Table 2 ).
The frequency of recovery room pain was similar between groups (end-hole=12%, triple-hole=15%, six-hole=10%, P=0.75; Table 2 ) and demonstrated strong evidence for equivalence: 90% confidence intervals for the difference between proportions was within the 15% pre-specified limit for the endhole versus triple-hole (-15, 8) and end-hole versus six-hole (-8, 12), and only marginally outside the limit for the triple-hole versus six-hole (-6, 16). These limits are the estimates for which equivalence can be concluded with 95% confidence. Neither time to first pain, "average" pain during the first 24 hours, "worst" pain during the first 24 hours, nor the other catheter function-related secondary outcomes were significantly different between groups (Table 3) .
There was no evidence of inadvertent catheter vascular cannulation in any patient. No patient demonstrated symptoms or signs of systemic local anaesthetic toxicity. No patient reported significant dyspnoea requiring more than simple reassurance, before or after hospital discharge.
DISCUSSION
This study showed no major differences between an end-hole, triple-hole and novel six-hole catheter when used for continuous interscalene analgesia after shoulder surgery. These results are in contrast to our previous study suggesting benefit from the multi-orifice design and from previous epidural catheter studies.
There is one notable difference between the current and previous study, which might explain the contrasting findings. The previous interscalene study was designed primarily to investigate the effect of catheter threading distance rather than orifice configuration 1 . Therefore, the apparent benefit of the multi-orifice configuration over the end-hole design in that study was likely due to the difference in catheter orifice positioning betweeen the endhole and multi-hole groups: the distal orifice of the multi-hole catheters were positioned >2 cm beyond the needle tip, >1.5 cm distal to the orifice position of the end-hole group.
A second possibility for the lack of orifice effect in the present study is that the ambulatory pump boluses were not delivered at a high enough pressure or flow to result in adequate multi-orifice flow from the multi-orifice catheters. Local anaesthetic spread from a multi-orifice catheter has been shown to depend on flow rate: below 80 ml/hour, multi-orifice catheters function like single-orifice catheters 8 . Above 100 ml/hour, double or even triple-orifice flow occurs. Therefore, flow was likely to be multiorifice for the intraoperative bolus (>400 ml/hour), double or multi-orifice during mandatory pump boluses (100 and 150 ml/hour-the unanticipated necessity to use two different infusion pumps with different bolus flow rates was a further limitation) and single-orifice during the background infusion (2 ml/hour) 8 . However, if local anaesthetic spread differed enough between the one, three or sixorifice catheters to significantly affect block quality, this would have almost certainly manifested as a difference in the frequency of PACU pain given the relatively low volume and concentration used for the primary local anaesthetic bolus (15 ml ropivacaine 0.375%) and its administration at >400 ml/hour. Previous epidural analgesia studies in labouring patients have shown multi-orifice catheters are associated with a reduction in unilateral block 3, 4 , missed segments 4 , and ultimately improved analgesia 2 with a reduced requirement for catheter manipulations 2, 4 . Anatomical factors could explain the contrasting findings with the present study. Epidural block, being a compartmental block, is known to be influenced by the presence of septae and inadvertent catheter advancement outside the epidural compartment via the intervertebral foramina. Multi-orifice catheters, therefore, have good reason to perform better than single orifice catheters under these unique anatomical conditions.
The study design warrants comment. Given continuous nerve blocks are used to control pain during the first few days after surgery, the logical primary outcome would be 24 or 48 hours postoperative pain. However, I used recovery room pain (yes/no) as the primary outcome in order to maximise detection of a catheter orifice-related treatment effect. First, our previous research experience with this (local anaesthetic via catheter only) technique has suggested any catheter-related effect is most likely to manifest as a difference in the proportion of patients reporting pain in PACU, while 24-hour outcomes (pain, ropivacaine bolus and tramadol consumption) will only manifest for larger effects 1, 9 . Second, the highest catheter flow rate/pressure (>400 ml/hour) occurred during administration of the primary local anaesthetic bolus. The primary local anaesthetic bolus would therefore have had the highest chance of resulting in differential local anaesthetic spread from an orifice configuration-related effect 8manifesting as a between-group difference in PACU pain. Similarly, the primary local anaesthetic dose (15 ml 0.375%) was deliberately selected to be just below the estimated catheter-administered ED95 for volume and concentration to prevent PACU pain (20 ml 0.375%) 5 . Fifteen ml of 0.375% was thought to be low enough to detect a between-group difference in PACU pain, while also associated with an acceptable incidence of PACU pain (10% to 15%). When interpreting this apparently high incidence of PACU pain, it is important to note that all but one patient (99.4%) became pain-free after a supplementary 15 ml bolus in PACU and were thus deemed to have had a successfully placed catheter. My preferred catheter placement technique involves blind catheter positioning a short distance beyond the ultrasound-confirmed needle tip. However, an alternative technique involves confirming catheter position by direct catheter visualisation or 'indirectly' by observation of catheter injectate spread 10 , although neither direct nor indirect catheter confirmation has been validated with a randomised trial 10 . Regardless, the catheter placement technique was consistent across groups and was further strengthened by being performed by an experienced operator: the ability to control for factors other than orifice configuration relied, in part, on the catheters in each group being consistently placed in the same position.
Catheter threading difficulty was more common for the end-hole catheters. Furthermore, although there was no difference in threading difficulty between the triple-hole and six-hole catheters as defined by marked threading resistance despite a 1 to 2 mm needle retraction, my observation was that catheter threading was easier for the new six-hole catheter. The end-hole catheter tip has a square shape, the triple-hole catheter has a curved 'bullet' shape tip, while the six-hole catheter has a 4 cm 'tapered' tip. The six-hole catheter also has a polyurethane coating, which is said to increase catheter tip flexibility. Either the catheter tip shape or flexibility, or both, might have contributed to these observed differences in catheter performance and further study is suggested to definitively test these observations. I performed the present study in the interscalene area. It is likely the results would apply to other areas such as the femoral and sciatic nerves. However, ideally, confirmatory studies should be conducted.
CONCLUSION
In summary, this study found no evidence to support the contention that catheter orifice configuration (end-hole, triple-hole or six-hole) significantly affects the quality of continuous interscalene analgesia. These findings are in contrast to epidural catheter studies, and suggest that anatomical factors have a significant bearing on whether multi-orifice catheters confer advantage over the single-orifice design.
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